DERMATOP® Emollient Cream (prednicarbate emollient cream) 0.1% contains prednicarbate, a synthetic corticosteroid for topical dermatologic use. Topical corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Each gram of DERMATOP Emollient Cream 0.1% contains 1.0 mg of prednicarbate.
DERMATOP Emollient Cream 0.1% is a medium-potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. DERMATOP Emollient Cream 0.1% may be used with caution in pediatric patients 1 year of age or older. The safety and efficacy of drug use for longer than 3 weeks in this population have not been established. Since safety and efficacy of DERMATOP Emollient Cream 0.1% have not been established in pediatric patients below 1 year of age, its use in this age group is not recommended.
Media Articles Related to Dermatop ( Topical)
In vitro effects of topical neuromodulatory medication on orofacial tissue
Source: Dentistry News From Medical News Today [2015.03.17]
At the 93rd General Session and Exhibition of the International Association for Dental Research, researcher M.J.
FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Source: MedicineNet brimonidine Specialty [2013.08.28]
Title: FDA Approves 1st Topical Gel to Ease Redness of Rosacea
Category: Health News
Created: 8/27/2013 12:35:00 PM
Last Editorial Review: 8/28/2013 12:00:00 AM
Burn Risk Seen with Topical Pain Relievers
Source: MedPage Today Product Alert [2012.09.13]
WASHINGTON -- The FDA warned Thursday of the risks of rare but serious chemical burns with certain over-the-counter topical pain relievers, including Bengay, Capzasin, Flexall, Icy Hot, and Mentholatum.
Drugs stimulate body's own stem cells to replace the brain cells lost in multiple sclerosis
Source: Multiple Sclerosis News From Medical News Today [2015.04.22]
A pair of topical medicines already alleviating skin conditions each may prove to have another, even more compelling use: instructing stem cells in the brain to reverse damage caused by multiple...
Clinical trial results of potential migraine therapy to be presented by Achelios Therapeutics
Source: Headache / Migraine News From Medical News Today [2015.04.21]
TOPOFEN (TM) is a new and novel topical medication for the treatment of acute migraineAchelios Therapeutics will announce results from a Phase IIa placebo-controlled clinical trial in moderate...
Published Studies Related to Dermatop ( Topical)
Effectiveness of topical curcumin for treatment of mastitis in breastfeeding
women: a randomized, double-blind, placebo-controlled clinical trial. 
inflammation in women suffering from lactational mastitis... CONCLUSION: The results of the current study indicate that topical preparation of
"Coffee plus honey" versus "topical steroid" in the treatment of
chemotherapy-induced oral mucositis: a randomised controlled trial. 
steroid, honey, honey plus coffee) in patients suffering from oral mucositis... CONCLUSION: Oral mucositis can be successfully treated by a combination of honey
Topical tetracaine used for 24 hours is safe and rated highly effective by
patients for the treatment of pain caused by corneal abrasions: a double-blind,
randomized clinical trial. 
of pain caused by corneal abrasions... CONCLUSIONS: Topical tetracaine used for 24 hours is safe, and while there was no
Efficacy and safety of topical Trikatu preparation in, relieving mosquito bite
reactions: a randomized controlled trial. 
mosquito bite reactions... CONCLUSION: Trikatu did not show additional effects for relieving mosquito bite
A phase III randomized, placebo-controlled study of topical amitriptyline and
ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of
Rochester CCOP study of 462 cancer survivors. 
efficacy of 2% ketamine plus 4% amitriptyline (KA) cream for reducing CIPN... CONCLUSIONS: This study suggests that KA cream does not decrease CIPN symptoms in
Clinical Trials Related to Dermatop ( Topical)
Standardized Time- and Score-Oriented Treatment of Moderate and Severe Atopic Dermatitis [Completed]
The study was designed to test the hypothesis whether a standardized, time-and score-oriented
treatment following a strict evidence based algorithm is equally effective to a standard
treatment regimen for moderate to severe atopic dermatitis.
Study Type: Mono-centre study, patients are blinded, physicians are randomized to either
treat study- or controll group
Eligible are patients age 2 years or older with SCORAD >= 20 Duration: 12 Months, study
visits every 4 weeks.
Primary endpoint is Difference between Baseline SCORAD and mean SCORAD under treatment.
Secundary endpoints are quality of life, safety and economic burden in both treatment
Fexofenadine in Pruritic Skin Disease [Completed]